{
  "abstract": "Lecanemab (Leqembi), the first drug to show an ability to slow cognitive decline in Alzheimer’s disease, will be available for home use in the US from 6 October, following the approval of a weekly subcutaneous injectable version by the Food and Drug Administration (FDA).",
  "authors": [
    {
      "affiliations": [
        "Montreal"
      ],
      "name": "Owen Dyer"
    }
  ],
  "title": "Injectable Alzheimer’s drug lecanemab approved in US for use at home",
  "uid": "eadae5f2-94ae-5c92-841b-65705a5f0449"
}